IRWD$4.50
$4.51
Chart
Performance
Key Stats
AI IRWD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldIronwood Pharmaceuticals presents a mixed investment profile. While it shows strong potential in its niche therapeutic areas and has a manageable debt level, recent performance and negative earnings are concerns. Technical indicators offer mixed signals, suggesting a cautious approach.
Thematic
Ironwood Pharmaceuticals operates in the growing fields of gastrointestinal (GI) and rare diseases, with a focus on innovative therapies. The company's product pipeline and strategic partnerships align with positive thematic trends in healthcare innovation and unmet medical needs.
Fundamental
Ironwood Pharmaceuticals shows a mixed fundamental picture. While its balance sheet is strengthening with reduced debt and increasing cash equivalents, recent EPS misses and current negative profitability are significant concerns. Valuation metrics are also challenging.
Technical
The stock has experienced significant volatility and a steep decline over the past year, but recent short-term performance shows some recovery. Technical indicators are mixed, with some suggesting potential for upward movement, but significant resistance levels remain.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 85 |
| Healthcare Market Trends | 70 |
| Partnerships and Collaborations | 80 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 30 |
| Balance Sheet Health | 40 |
| Cash Flow | 70 |
| Earnings Performance | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 15 |
| Momentum | 50 |
| Moving Averages | 65 |
| Support and Resistance | 50 |
| Volume Analysis | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
The company has exceeded EPS estimates in recent quarters (e.g., Q3 2023 showed a 25.67% positive surprise), indicating better-than-expected profitability and operational efficiency.
Improving P/S Ratio
The Price-to-Sales (P/S) ratio has decreased from 4.6 in 2021 to 0.3 in 2023, suggesting the company's market valuation is becoming more attractive relative to its revenue generation.
Bearish Points (8)
Consistent EPS Misses
Recent quarterly reports show consistent misses on EPS estimates (e.g., Q2 2024 reported -0.02 vs. estimate of 0.19), suggesting significant challenges in meeting profitability expectations.
Negative Earnings and High P/E
The company has a negative P/E ratio (e.g., -4.2 TTM) due to net losses, making traditional valuation metrics less meaningful and indicating potential overvaluation if profitability does not materialize.
Calendar
August 2025
7
Next Earnings Date
H: $0.04
A: $0.04
L: $0.04
H: 68.30M
A: 62.02M
L: 54.00M
Profile
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Seasonals
Price Target
0.95 USD
The 39 analysts offering 1 year price forecasts for IRWD have a max estimate of 1.10 and a min estimate of 0.70.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Largest publicly traded U.S. water and wastewater utility.
Weight: 95
Diversified publicly traded U.S. water, wastewater, and natural gas utility.
Weight: 93
Major water utility with significant operations in California, Texas, and Maine.
Weight: 92
Largest investor-owned water utility in California by customers served.